Charles Stanley Direct

ISAs, SIPPs and JISAs for self-directed investors

Charles Stanley is a UK investment management company. It was established in 1792 and is one of the oldest firms on the London Stock Exchange.

Charles Stanley Group provides investment and wealth management services to private clients, charities and smaller institutions. Products offered include stocks and shares ISAs, SIPPs, JISAs, investment accounts and discretionary and advisory services.

Charles Stanley is also a signatory to the Women in Finance Charter, the government-led initiative designed to encourage gender balance at all levels across financial services firms.

Pensions

25% of people are forfeiting their pension contribution to deal with cost-of-living crisis

Women bearing biggest financial burden

13 July 2022 • 3 min read

Global

Deep Dive: Global equity income funds pick inflation winners

Sustainable pricing power will be key

08 July 2022 • 5 min read

Industry

Revealed: Winners of the Investment Marketing & Innovation Awards 2022

Winners announced at in-person ceremony

07 July 2022 • 2 min read

Companies

Stock Spotlight: Wizz Air remains firmly grounded as sky-high fuel costs take toll

Plagued by issues

27 June 2022 • 6 min read

Investment Trusts

Only a 'handful' of managers to join Baillie Gifford and Fidelity in race for unlisted assets in trusts

11 trusts since 2018

12 April 2022 • 4 min read

ESG

Charles Stanley unveils responsible model portfolios range

Low-cost ETFs

07 April 2022 • 1 min read

Investment Trusts

The trusts with the biggest discount/premium changes since the crisis

Jupiter Green seen discount narrow 10%

10 March 2022 • 4 min read

Companies

Tilney Smith & Williamson hires from Charles Stanley for investment director role

Sean O’Flanagan

09 March 2022 • 1 min read

Investment Trusts

Questions over music royalty trusts following Neil Young's Spotify row

Hipgnosis on 8.4% discount

04 February 2022 • 3 min read

Investment

Unilever steady after chilly few weeks

Unilever has faced a tumultuous few weeks as news of its failed £50bn bid to buy GlaxoSmithKline’s consumer health unit came to light along with job cuts, scathing remarks from star fund managers and an activist investor taking a position.

03 February 2022 • 4 min read